CDA | Evidence Driven
CDA | Evidence Driven

etrasimod

Details

Files
Generic Name:
etrasimod
Project Status:
Active
Therapeutic Area:
Ulcerative colitis
Manufacturer:
Pfizer Canada ULC
Call for patient/clinician input open:
Brand Name:
Velsipity
Project Line:
Reimbursement Review
Project Number:
SR0795-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or an advanced treatment.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​ For the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or an advanced treatment.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open08-Dec-23
Call for patient/clinician input closed12-Feb-24
Clarification:

- Patient input submission received from Crohn's and Colitis Canada and Gastrointestinal Society

Submission received05-Feb-24
Submission accepted20-Feb-24
Review initiated21-Feb-24
Draft CADTH review report(s) provided to sponsor for comment14-May-24
Deadline for sponsors comments24-May-24
CADTH review report(s) and responses to comments provided to sponsor14-Jun-24
Expert committee meeting (initial)26-Jun-24
Draft recommendation issued to sponsor10-Jul-24
Draft recommendation posted for stakeholder feedback18-Jul-24
End of feedback period01-Aug-24
Final recommendation issued to sponsor and drug plans14-Aug-24
Final recommendation posted30-Aug-24
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)28-Aug-24
CADTH review report(s) posted-

Files

Recommendation and Reason View PDF
Patient and Clinician Group Input View PDF
Last Updated : October 17, 2024